A Randomized, Dose-Ranging, Safety and Tolerability Study of NBI-3001 Administered by Continuous Intratumoral Infusion Followed by Surgical Resection in Patients With Recurrent Glioblastoma Multiforme
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2013
At a glance
- Drugs MDNA 55 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Neurocrine Biosciences
- 25 Jul 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
- 24 Sep 2005 New trial record.